Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Axogen Inc (AXGN)

Axogen Inc (AXGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 667,026
  • Shares Outstanding, K 39,469
  • Annual Sales, $ 83,940 K
  • Annual Income, $ -22,400 K
  • 60-Month Beta 0.28
  • Price/Sales 7.98
  • Price/Cash Flow N/A
  • Price/Book 4.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.20
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.80 +14.19%
on 11/20/19
17.71 -4.57%
on 12/02/19
+1.58 (+10.31%)
since 11/13/19
3-Month
10.91 +54.90%
on 10/10/19
17.71 -4.57%
on 12/02/19
+2.55 (+17.77%)
since 09/13/19
52-Week
10.91 +54.90%
on 10/10/19
29.59 -42.89%
on 12/14/18
-12.19 (-41.90%)
since 12/13/18

Most Recent Stories

More News
Avance(R) Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade(R) Float

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced Jessica de Paz has been selected to...

AXGN : 16.90 (-0.47%)
Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO,...

AXGN : 16.90 (-0.47%)
Axogen, Inc. to Participate at Jefferies London Healthcare Conference

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO,...

AXGN : 16.90 (-0.47%)
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

AXGN : 16.90 (-0.47%)
Axogen, Inc. Reports 2019 Third Quarter Financial Results

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today reported financial results and business highlights...

AXGN : 16.90 (-0.47%)
Earnings Preview: AxoGen (AXGN) Q3 Earnings Expected to Decline

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXGN : 16.90 (-0.47%)
Optometry Market Extensive Study 2019 By Key Players Analysis – TOPCON CORPORATION, F. Hoffmann-La Roche Ltd., Pfizer, Inc.

The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the Global. It includes Porter's Five Forces and PESTLE...

AGN : 188.34 (+0.04%)
NVS : 92.99 (-0.08%)
PFE : 38.33 (-0.54%)
TOPCF : 13.4875 (+1.64%)
VRX.TO : 30.80 (-3.33%)
MRK : 89.19 (-0.42%)
MDT : 113.52 (+1.01%)
ABT : 86.35 (+0.44%)
AXGN : 16.90 (-0.47%)
ORGO : 4.90 (+4.26%)
QURE : 73.97 (+7.39%)
VCEL : 17.64 (-0.73%)
TMO : 320.50 (+0.36%)
A : 83.71 (-1.30%)
MMM : 168.79 (+0.14%)
Legal Marijuana Market Analysis By Canopy Growth, Aphria, Aurora Cannabis, Maricann, Tilray

Chicago, United States, Oct 23, 2019 The research report provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product...

ACB.TO : 3.47 (+0.87%)
MRK : 89.19 (-0.42%)
MDT : 113.52 (+1.01%)
ABT : 86.35 (+0.44%)
AXGN : 16.90 (-0.47%)
ORGO : 4.90 (+4.26%)
QURE : 73.97 (+7.39%)
VCEL : 17.64 (-0.73%)
TMO : 320.50 (+0.36%)
A : 83.71 (-1.30%)
MMM : 168.79 (+0.14%)
Axogen, Inc. to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter...

AXGN : 16.90 (-0.47%)
Scott+Scott Attorneys at Law LLP Investigating Axogen, Inc.'s Directors and Officers for Breach of Fiduciary Duties - AXGN

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Axogen, Inc. ("Axogen") (NASDAQ:...

AXGN : 16.90 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade AXGN with:

Business Summary

AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch...

See More

Key Turning Points

2nd Resistance Point 17.30
1st Resistance Point 17.10
Last Price 16.90
1st Support Level 16.69
2nd Support Level 16.48

See More

52-Week High 29.59
Fibonacci 61.8% 22.45
Fibonacci 50% 20.25
Fibonacci 38.2% 18.05
Last Price 16.90
52-Week Low 10.91

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar